2023 was a banner year for Dexcom. Not only did it undertake a new major product launch, but it received the largest expansion of insurance coverage in the company’s history. And it’s got the receipts to show for it.

Computing behemoth Nvidia is expanding its march into drug development, announcing a new partnership with Amgen's deCode and adding Recursion to its AI-based discovery platform.

Blueprint Medicines is pulling back from one of its three areas of focus, dropping two non-small cell lung cancer (NSCLC) programs in response to early clinical data on the EGFR tyrosine kinase inhibitors.

Two successful phase 3 trials put Astellas’ monoclonal antibody zolbetuximab on track to become the first approved therapy to treat one of the hottest targets in oncology—tumors that are claudin (CLDN) positive. But the Japanese company will have to clear up manufacturing issues first. The FDA has sent a complete response letter to Astellas, rejecting zolbetuximab because of unresolved deficiencies identified in a pre-license inspection of a third-party manufacturing facility.

Hot on the heels of the official launch of its artificial intelligence-focused initiative, Flagship Pioneering is debuting yet another advanced technology-centric project.

With Novo Nordisk and Eli Lilly dominating the obesity field, Amgen's CEO Robert Bradway knows a new offering will have to offer a unique benefit. Amgen's phase 2 candidate MariTide, plus a myriad of preclinical assets, could stand out from the crowd with a differentiated approach, the CEO figures.

The center, which will be based at the headquarters of Doudna’s own Innovative Genomics Institute (IGI), will be known as the Danaher-IGI Beacon for CRISPR Cures.